Watch ACAD. Know when insiders buy.
One email the day a filing lands. Free.
ACAD
ACADIA PHARMACEUTICALS INC
28.02
+0.16 +0.57%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
85
PASS · shorts 85
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.8BP/E 12.6DIV YIELD —FCF YIELD 3.02%REV TTM $1.1B +11.8%NET INCOME $380.5M +71.3%NET CASH $385M52W 20.06 – 30.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $308M | +16.4% | 90.8% | $37.8M | $31.5M | +18.1% | 0.18 | $100.8M | $5.1M | $95.7M | Aug 5 |
| Q1 2026 · Mar 31 | $268.1M | +9.7% | 90.8% | −$4.6M | $3.6M | −80.8% | 0.02 | $34M | $5.2M | $28.8M | May 7 |
| Q4 2025 · Dec 31derived | $284M | +9.4% | 90.8% | $17.4M | $273.6M | +90.3% | 1.61 | −$48.7M | $4M | −$52.7M | Feb 26 |
| Q3 2025 · Sep 30 | $278.6M | +11.3% | 92.2% | $35.8M | $71.8M | +119.1% | 0.42 | $74.3M | $388K | $73.9M | Nov 6 |
| Q2 2025 · Jun 30 | $264.6M | +9.3% | 92.2% | $32.4M | $26.7M | −20.1% | 0.16 | $64M | $297K | $63.7M | Aug 5 |
| Q1 2025 · Mar 31 | $244.3M | +18.7% | 91.7% | $19.3M | $19M | +14.7% | 0.11 | $20.3M | $0 | $20.3M | May 7 |
| Q4 2024 · Dec 31derived | $259.6M | +12.4% | 91.6% | $153.5M | $143.7M | +213.9% | 0.86 | $40.4M | $453K | $39.9M | Feb 26 |
| Q3 2024 · Sep 30 | $250.4M | +18.3% | 92.5% | $31.6M | $32.8M | — | 0.20 | $63.2M | $70K | $63.2M | Nov 6 |
| Q2 2024 · Jun 30 | $242M | — | 92.5% | $30.4M | $33.4M | — | 0.20 | $25M | — | — | Aug 7 |
| Q1 2024 · Mar 31 | $205.8M | — | 88.8% | $15.2M | $16.6M | — | 0.10 | $29.1M | — | — | May 8 |
| Q4 2023 · Dec 31 | $231M | — | 92.3% | $34.9M | $45.8M | — | 0.28 | $85.4M | $0 | $85.4M | Feb 26 |
| Q3 2023 · Sep 30 | $211.7M | — | 93.1% | −$57.8M | −$65.2M | — | -0.40 | −$59M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.1B | 91.7% | $104.8M | $391M | 36.5% | 2.30 | $109.8M | $4.7M | $105.1M | — | — |
| FY2024 · to Dec 31 | $957.8M | 91.5% | $230.8M | $226.5M | 23.6% | 1.36 | $157.7M | $523K | $157.2M | — | — |
| FY2023 · to Dec 31 | $726.4M | 94.3% | −$73.4M | −$61.3M | -8.4% | -0.37 | $16.7M | $50K | $16.7M | — | — |
| FY2022 · to Dec 31 | $517.2M | 98.0% | −$223.6M | −$216M | -41.8% | -1.34 | −$114M | $0 | −$114M | — | — |
| FY2021 · to Dec 31 | $484.1M | 97.8% | −$170.4M | −$167.9M | -34.7% | -1.05 | −$125.7M | $1.1M | −$126.8M | — | — |
| FY2020 · to Dec 31 | $441.8M | 97.7% | −$286.6M | −$281.6M | -63.7% | -1.79 | −$136.2M | $7.6M | −$143.8M | — | — |
Every number comes from ACADIA PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.